Article info

Download PDFPDF
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups

Authors

  1. Correspondence to Professor Sandro Pignata, Gynaecological Oncology, National Cancer Institute Napels, Naples, Italy; s.pignata{at}istitutotumori.na.it
View Full Text

Citation

Schettino C, Musacchio L, Bartoletti M, et al
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups

Publication history

  • Accepted March 7, 2022
  • First published March 22, 2022.
Online issue publication 
May 18, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.